Oncology Frontier:As a member of the NCCN guidelines panel， can you outline the recent changes that have occurred in the guidelines as they relate to triple-negative breast cancer?

　　《肿瘤瞭望》： NCCN乳腺癌指南在三阴性乳腺癌部分有无更新？

　　Dr Telli: There aren’t any major changes to the guidelines at this point in time related to triple-negative breast cancer， but I am hopeful that in the future， based on the results of this TNT trial in metastatic disease， that with longer follow-up and if the superior results in the BRCAmutation carrier population are maintained， then this will ultimately lead to a change in the guidelines with a preference for carboplatin in these advanced triple-negative breast cancer patients in the setting of a BRCAmutation. In the early stage setting with standard chemotherapy (anthracycline- and taxane-based)， we need further studies to determine which patients should be standardly receiving platinum with newly diagnosed triple-negative breast cancer.

　　Telli博士：三阴性乳腺癌的最近没什么大的变化。在TNT试验以后随访中，若卡铂治疗BRCA突变转移性三阴乳腺癌的优良效果能继续保持，则有希望改变NCCN指南推荐。对于早期三阴性乳腺癌，还需要进一步研究以确定哪些初诊患者应接受标准铂类化疗。